Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2022

Start date
07 Mar 2022
End date
09 Mar 2022
Paris, France

Save the Date!

The home of Phase 1 in oncology 

The ESMO Targeted Anticancer Therapies Congress 2022, known as “The Home of Phase I in Oncology” will offer participants a glimpse of the future of targeted anticancer therapies.

This year's congress will take place as an onsite event, on 7-9 March 2022 in Paris, France, while also providing online access.  

TAT is the premier international meeting focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development. 

Stakeholders from academy and industry will discuss with clinicians, researchers and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide. 

Scientific Co-Chairs

  • Ruth Plummer, Newcastle-upon-Tyne, UK
  • Lillian Siu, Toronto, ON, Canada


ESMO Head Office
Via Ginevra 4, 6900 Lugano 



The abstract submission for TAT 2022 is now open!

TAT map block image


The ESMO Targeted Anticancer Therapies 2022 (TAT) will take place at the Palais des Congrès de Paris, France. 



Get in touch with the organisers of ESMO TAT 2022. You'll find the contact details here

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings